Literature DB >> 22278255

Analysis of hepatitis C virus intrahost diversity across the coding region by ultradeep pyrosequencing.

Michael Lauck1, Mónica V Alvarado-Mora, Ericka A Becker, Dipankar Bhattacharya, Rob Striker, Austin L Hughes, Flair J Carrilho, David H O'Connor, João R Rebello Pinho.   

Abstract

Hepatitis C virus (HCV) is the leading cause of liver disease worldwide. In this study, we analyzed four treatment-naïve patients infected with subtype 1a and performed Roche/454 pyrosequencing across the coding region. We report the presence of low-level drug resistance mutations that would most likely have been missed using conventional sequencing methods. The approach described here is broadly applicable to studies of viral diversity and could help to improve the efficacy of direct-acting antiviral agents (DAA) in the treatment of HCV-infected patients.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22278255      PMCID: PMC3302523          DOI: 10.1128/JVI.06627-11

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  34 in total

Review 1.  Replication of hepatitis C virus.

Authors:  R Bartenschlager; V Lohmann
Journal:  J Gen Virol       Date:  2000-07       Impact factor: 3.891

Review 2.  Molecular biology of hepatitis C virus.

Authors:  Tetsuro Suzuki; Hideki Aizaki; Kyoko Murakami; Ikuo Shoji; Takaji Wakita
Journal:  J Gastroenterol       Date:  2007-06-29       Impact factor: 7.527

Review 3.  Hepatitis C virus resistance to protease inhibitors.

Authors:  Philippe Halfon; Stephen Locarnini
Journal:  J Hepatol       Date:  2011-02-01       Impact factor: 25.083

4.  A long-term study of hepatitis C virus replication in non-A, non-B hepatitis.

Authors:  P Farci; H J Alter; D Wong; R H Miller; J W Shih; B Jett; R H Purcell
Journal:  N Engl J Med       Date:  1991-07-11       Impact factor: 91.245

Review 5.  Hepatitis C virus population dynamics during infection.

Authors:  J M Pawlotsky
Journal:  Curr Top Microbiol Immunol       Date:  2006       Impact factor: 4.291

6.  Fidelity of HIV-1 reverse transcriptase copying RNA in vitro.

Authors:  J P Ji; L A Loeb
Journal:  Biochemistry       Date:  1992-02-04       Impact factor: 3.162

7.  Natural prevalence of hepatitis C virus variants with decreased sensitivity to NS3.4A protease inhibitors in treatment-naive subjects.

Authors:  Doug J Bartels; Yi Zhou; Eileen Z Zhang; Michelle Marcial; Randal A Byrn; Thomas Pfeiffer; Ann M Tigges; Bambang S Adiwijaya; Chao Lin; Ann D Kwong; Tara L Kieffer
Journal:  J Infect Dis       Date:  2008-09-15       Impact factor: 5.226

8.  Hepatitis C virus (HCV) circulates as a population of different but closely related genomes: quasispecies nature of HCV genome distribution.

Authors:  M Martell; J I Esteban; J Quer; J Genescà; A Weiner; R Esteban; J Guardia; J Gómez
Journal:  J Virol       Date:  1992-05       Impact factor: 5.103

9.  Rapid sequence variation of the hypervariable region of hepatitis C virus during the course of chronic infection.

Authors:  M Kurosaki; N Enomoto; F Marumo; C Sato
Journal:  Hepatology       Date:  1993-12       Impact factor: 17.425

10.  Binding site characterization and resistance to a class of non-nucleoside inhibitors of the hepatitis C virus NS5B polymerase.

Authors:  George Kukolj; Graham A McGibbon; Ginette McKercher; Martin Marquis; Sylvain Lefèbvre; Louise Thauvette; Jean Gauthier; Sylvie Goulet; Marc-André Poupart; Pierre L Beaulieu
Journal:  J Biol Chem       Date:  2005-09-27       Impact factor: 5.157

View more
  28 in total

1.  Genotype- and Subtype-Independent Full-Genome Sequencing Assay for Hepatitis C Virus.

Authors:  Charlotte Hedskog; Krishna Chodavarapu; Karin S Ku; Simin Xu; Ross Martin; Michael D Miller; Hongmei Mo; Evguenia Svarovskaia
Journal:  J Clin Microbiol       Date:  2015-04-15       Impact factor: 5.948

2.  Deep sequencing identifies two genotypes and high viral genetic diversity of human pegivirus (GB virus C) in rural Ugandan patients.

Authors:  Ria R Ghai; Samuel D Sibley; Michael Lauck; Jorge M Dinis; Adam L Bailey; Colin A Chapman; Patrick Omeja; Thomas C Friedrich; David H O'Connor; Tony L Goldberg
Journal:  J Gen Virol       Date:  2013-09-28       Impact factor: 3.891

Review 3.  Hepatitis C virus molecular evolution: transmission, disease progression and antiviral therapy.

Authors:  Maria Victoria Preciado; Pamela Valva; Alejandro Escobar-Gutierrez; Paula Rahal; Karina Ruiz-Tovar; Lilian Yamasaki; Carlos Vazquez-Chacon; Armando Martinez-Guarneros; Juan Carlos Carpio-Pedroza; Salvador Fonseca-Coronado; Mayra Cruz-Rivera
Journal:  World J Gastroenterol       Date:  2014-11-21       Impact factor: 5.742

Review 4.  Within-host nucleotide diversity of virus populations: insights from next-generation sequencing.

Authors:  Chase W Nelson; Austin L Hughes
Journal:  Infect Genet Evol       Date:  2014-12-04       Impact factor: 3.342

5.  Rapid hepatitis C virus divergence among chronically infected individuals.

Authors:  Mayra Cruz-Rivera; Juan Carlos Carpio-Pedroza; Alejandro Escobar-Gutiérrez; Daniela Lozano; Arely Vergara-Castaneda; Pilar Rivera-Osorio; Armando Martinez-Guarneros; Carlos A Vazquez Chacon; Salvador Fonseca-Coronado; Gilberto Vaughan
Journal:  J Clin Microbiol       Date:  2012-12-05       Impact factor: 5.948

6.  Ultradeep sequencing study of chronic hepatitis C virus genotype 1 infection in patients treated with daclatasvir, peginterferon, and ribavirin.

Authors:  Eisuke Murakami; Michio Imamura; C Nelson Hayes; Hiromi Abe; Nobuhiko Hiraga; Yoji Honda; Atsushi Ono; Keiichi Kosaka; Tomokazu Kawaoka; Masataka Tsuge; Hiroshi Aikata; Shoichi Takahashi; Daiki Miki; Hidenori Ochi; Hirotaka Matsui; Akinori Kanai; Toshiya Inaba; Fiona McPhee; Kazuaki Chayama
Journal:  Antimicrob Agents Chemother       Date:  2014-01-27       Impact factor: 5.191

7.  Pretreatment resistance to hepatitis C virus protease inhibitors boceprevir/telaprevir in hepatitis C virus subgenotype 1a-infected patients from Manitoba.

Authors:  Anton Andonov; Kamran Kadkhoda; Carla Osiowy; Kelly Kaita
Journal:  Can J Gastroenterol       Date:  2013-07       Impact factor: 3.522

8.  Whole genome pyrosequencing of rare hepatitis C virus genotypes enhances subtype classification and identification of naturally occurring drug resistance variants.

Authors:  Ruchi M Newman; Thomas Kuntzen; Brian Weiner; Andrew Berical; Patrick Charlebois; Carla Kuiken; Donald G Murphy; Peter Simmonds; Phil Bennett; Niall J Lennon; Bruce W Birren; Michael C Zody; Todd M Allen; Matthew R Henn
Journal:  J Infect Dis       Date:  2012-11-06       Impact factor: 5.226

9.  Measurements of Intrahost Viral Diversity Are Extremely Sensitive to Systematic Errors in Variant Calling.

Authors:  John T McCrone; Adam S Lauring
Journal:  J Virol       Date:  2016-07-11       Impact factor: 5.103

10.  Naturally occurring dominant drug resistance mutations occur infrequently in the setting of recently acquired hepatitis C.

Authors:  Tanya L Applegate; Silvana Gaudieri; Anne Plauzolles; Abha Chopra; Jason Grebely; Michaela Lucas; Margaret Hellard; Fabio Luciani; Gregory J Dore; Gail V Matthews
Journal:  Antivir Ther       Date:  2014-08-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.